nodes	percent_of_prediction	percent_of_DWPC	metapath
Deferoxamine—Scab—Fluorouracil—head and neck cancer	0.048	0.048	CcSEcCtD
Deferoxamine—Lung infiltration—Hydroxyurea—head and neck cancer	0.0452	0.0452	CcSEcCtD
Deferoxamine—Acute respiratory distress syndrome—Docetaxel—head and neck cancer	0.0422	0.0422	CcSEcCtD
Deferoxamine—Local reaction—Fluorouracil—head and neck cancer	0.0275	0.0275	CcSEcCtD
Deferoxamine—Rash generalised—Docetaxel—head and neck cancer	0.0259	0.0259	CcSEcCtD
Deferoxamine—Bone pain—Vinblastine—head and neck cancer	0.0243	0.0243	CcSEcCtD
Deferoxamine—Renal failure acute—Hydroxyurea—head and neck cancer	0.0167	0.0167	CcSEcCtD
Deferoxamine—Liver disorder—Docetaxel—head and neck cancer	0.0162	0.0162	CcSEcCtD
Deferoxamine—Scotoma—Docetaxel—head and neck cancer	0.0145	0.0145	CcSEcCtD
Deferoxamine—Blood creatinine increased—Hydroxyurea—head and neck cancer	0.0144	0.0144	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Vinblastine—head and neck cancer	0.0127	0.0127	CcSEcCtD
Deferoxamine—Swelling—Fluorouracil—head and neck cancer	0.0126	0.0126	CcSEcCtD
Deferoxamine—Dysuria—Hydroxyurea—head and neck cancer	0.0124	0.0124	CcSEcCtD
Deferoxamine—Bone disorder—Docetaxel—head and neck cancer	0.0122	0.0122	CcSEcCtD
Deferoxamine—Infestation—Hydroxyurea—head and neck cancer	0.0119	0.0119	CcSEcCtD
Deferoxamine—Infestation NOS—Hydroxyurea—head and neck cancer	0.0119	0.0119	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Hydroxyurea—head and neck cancer	0.0116	0.0116	CcSEcCtD
Deferoxamine—Bone pain—Docetaxel—head and neck cancer	0.0115	0.0115	CcSEcCtD
Deferoxamine—Injection site reaction—Docetaxel—head and neck cancer	0.0109	0.0109	CcSEcCtD
Deferoxamine—Hallucination—Hydroxyurea—head and neck cancer	0.0106	0.0106	CcSEcCtD
Deferoxamine—Neuropathy—Docetaxel—head and neck cancer	0.0103	0.0103	CcSEcCtD
Deferoxamine—Angiopathy—Hydroxyurea—head and neck cancer	0.00965	0.00965	CcSEcCtD
Deferoxamine—Eosinophilia—Fluorouracil—head and neck cancer	0.00947	0.00947	CcSEcCtD
Deferoxamine—Erythema—Hydroxyurea—head and neck cancer	0.00926	0.00926	CcSEcCtD
Deferoxamine—Leukopenia—Vinblastine—head and neck cancer	0.00909	0.00909	CcSEcCtD
Deferoxamine—Swelling—Docetaxel—head and neck cancer	0.00906	0.00906	CcSEcCtD
Deferoxamine—Convulsion—Vinblastine—head and neck cancer	0.0088	0.0088	CcSEcCtD
Deferoxamine—Infestation NOS—Fluorouracil—head and neck cancer	0.00853	0.00853	CcSEcCtD
Deferoxamine—Infestation—Fluorouracil—head and neck cancer	0.00853	0.00853	CcSEcCtD
Deferoxamine—Visual disturbance—Docetaxel—head and neck cancer	0.00843	0.00843	CcSEcCtD
Deferoxamine—Renal impairment—Docetaxel—head and neck cancer	0.0084	0.0084	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Fluorouracil—head and neck cancer	0.00836	0.00836	CcSEcCtD
Deferoxamine—Leukopenia—Hydroxyurea—head and neck cancer	0.00829	0.00829	CcSEcCtD
Deferoxamine—Thrombocytopenia—Vinblastine—head and neck cancer	0.00812	0.00812	CcSEcCtD
Deferoxamine—Convulsion—Hydroxyurea—head and neck cancer	0.00803	0.00803	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.00783	0.00783	CcSEcCtD
Deferoxamine—Oedema—Hydroxyurea—head and neck cancer	0.00756	0.00756	CcSEcCtD
Deferoxamine—Infection—Hydroxyurea—head and neck cancer	0.00751	0.00751	CcSEcCtD
Deferoxamine—Paraesthesia—Vinblastine—head and neck cancer	0.00744	0.00744	CcSEcCtD
Deferoxamine—Nervous system disorder—Hydroxyurea—head and neck cancer	0.00741	0.00741	CcSEcCtD
Deferoxamine—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.0074	0.0074	CcSEcCtD
Deferoxamine—Skin disorder—Hydroxyurea—head and neck cancer	0.00734	0.00734	CcSEcCtD
Deferoxamine—Pain—Vinblastine—head and neck cancer	0.00709	0.00709	CcSEcCtD
Deferoxamine—Arrhythmia—Fluorouracil—head and neck cancer	0.00684	0.00684	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Vinblastine—head and neck cancer	0.00678	0.00678	CcSEcCtD
Deferoxamine—Dyspnoea—Hydroxyurea—head and neck cancer	0.00674	0.00674	CcSEcCtD
Deferoxamine—Erythema—Fluorouracil—head and neck cancer	0.00667	0.00667	CcSEcCtD
Deferoxamine—Abdominal pain—Vinblastine—head and neck cancer	0.00655	0.00655	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.00653	0.00653	CcSEcCtD
Deferoxamine—Pain—Hydroxyurea—head and neck cancer	0.00646	0.00646	CcSEcCtD
Deferoxamine—Vision blurred—Fluorouracil—head and neck cancer	0.00628	0.00628	CcSEcCtD
Deferoxamine—Infestation NOS—Docetaxel—head and neck cancer	0.00616	0.00616	CcSEcCtD
Deferoxamine—Infestation—Docetaxel—head and neck cancer	0.00616	0.00616	CcSEcCtD
Deferoxamine—Hypersensitivity—Vinblastine—head and neck cancer	0.00611	0.00611	CcSEcCtD
Deferoxamine—Renal failure—Docetaxel—head and neck cancer	0.00605	0.00605	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Docetaxel—head and neck cancer	0.00604	0.00604	CcSEcCtD
Deferoxamine—Body temperature increased—Hydroxyurea—head and neck cancer	0.00598	0.00598	CcSEcCtD
Deferoxamine—Leukopenia—Fluorouracil—head and neck cancer	0.00597	0.00597	CcSEcCtD
Deferoxamine—Convulsion—Fluorouracil—head and neck cancer	0.00578	0.00578	CcSEcCtD
Deferoxamine—Myalgia—Fluorouracil—head and neck cancer	0.00568	0.00568	CcSEcCtD
Deferoxamine—Diarrhoea—Vinblastine—head and neck cancer	0.00567	0.00567	CcSEcCtD
Deferoxamine—Hypersensitivity—Hydroxyurea—head and neck cancer	0.00557	0.00557	CcSEcCtD
Deferoxamine—Dizziness—Vinblastine—head and neck cancer	0.00548	0.00548	CcSEcCtD
Deferoxamine—Urinary tract disorder—Docetaxel—head and neck cancer	0.00546	0.00546	CcSEcCtD
Deferoxamine—Anaphylactic shock—Fluorouracil—head and neck cancer	0.00544	0.00544	CcSEcCtD
Deferoxamine—Oedema—Fluorouracil—head and neck cancer	0.00544	0.00544	CcSEcCtD
Deferoxamine—Connective tissue disorder—Docetaxel—head and neck cancer	0.00543	0.00543	CcSEcCtD
Deferoxamine—Urethral disorder—Docetaxel—head and neck cancer	0.00542	0.00542	CcSEcCtD
Deferoxamine—Infection—Fluorouracil—head and neck cancer	0.00541	0.00541	CcSEcCtD
Deferoxamine—Nervous system disorder—Fluorouracil—head and neck cancer	0.00534	0.00534	CcSEcCtD
Deferoxamine—Thrombocytopenia—Fluorouracil—head and neck cancer	0.00533	0.00533	CcSEcCtD
Deferoxamine—Visual impairment—Docetaxel—head and neck cancer	0.00533	0.00533	CcSEcCtD
Deferoxamine—Tachycardia—Fluorouracil—head and neck cancer	0.00531	0.00531	CcSEcCtD
Deferoxamine—Vomiting—Vinblastine—head and neck cancer	0.00527	0.00527	CcSEcCtD
Deferoxamine—Headache—Vinblastine—head and neck cancer	0.00519	0.00519	CcSEcCtD
Deferoxamine—Diarrhoea—Hydroxyurea—head and neck cancer	0.00517	0.00517	CcSEcCtD
Deferoxamine—Eye disorder—Docetaxel—head and neck cancer	0.00517	0.00517	CcSEcCtD
Deferoxamine—Hypotension—Fluorouracil—head and neck cancer	0.00508	0.00508	CcSEcCtD
Deferoxamine—Angiopathy—Docetaxel—head and neck cancer	0.00502	0.00502	CcSEcCtD
Deferoxamine—Dizziness—Hydroxyurea—head and neck cancer	0.005	0.005	CcSEcCtD
Deferoxamine—Immune system disorder—Docetaxel—head and neck cancer	0.00499	0.00499	CcSEcCtD
Deferoxamine—Mediastinal disorder—Docetaxel—head and neck cancer	0.00498	0.00498	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.00496	0.00496	CcSEcCtD
Deferoxamine—Arrhythmia—Docetaxel—head and neck cancer	0.00494	0.00494	CcSEcCtD
Deferoxamine—Nausea—Vinblastine—head and neck cancer	0.00492	0.00492	CcSEcCtD
Deferoxamine—Paraesthesia—Fluorouracil—head and neck cancer	0.00489	0.00489	CcSEcCtD
Deferoxamine—Dyspnoea—Fluorouracil—head and neck cancer	0.00485	0.00485	CcSEcCtD
Deferoxamine—Erythema—Docetaxel—head and neck cancer	0.00481	0.00481	CcSEcCtD
Deferoxamine—Vomiting—Hydroxyurea—head and neck cancer	0.00481	0.00481	CcSEcCtD
Deferoxamine—Headache—Hydroxyurea—head and neck cancer	0.00474	0.00474	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.0047	0.0047	CcSEcCtD
Deferoxamine—Pain—Fluorouracil—head and neck cancer	0.00465	0.00465	CcSEcCtD
Deferoxamine—Muscle spasms—Docetaxel—head and neck cancer	0.00463	0.00463	CcSEcCtD
Deferoxamine—Nausea—Hydroxyurea—head and neck cancer	0.00449	0.00449	CcSEcCtD
Deferoxamine—Urticaria—Fluorouracil—head and neck cancer	0.00432	0.00432	CcSEcCtD
Deferoxamine—Leukopenia—Docetaxel—head and neck cancer	0.00431	0.00431	CcSEcCtD
Deferoxamine—Body temperature increased—Fluorouracil—head and neck cancer	0.0043	0.0043	CcSEcCtD
Deferoxamine—Convulsion—Docetaxel—head and neck cancer	0.00417	0.00417	CcSEcCtD
Deferoxamine—Arthralgia—Docetaxel—head and neck cancer	0.0041	0.0041	CcSEcCtD
Deferoxamine—Myalgia—Docetaxel—head and neck cancer	0.0041	0.0041	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.00407	0.00407	CcSEcCtD
Deferoxamine—Hypersensitivity—Fluorouracil—head and neck cancer	0.00401	0.00401	CcSEcCtD
Deferoxamine—Anaphylactic shock—Docetaxel—head and neck cancer	0.00393	0.00393	CcSEcCtD
Deferoxamine—Oedema—Docetaxel—head and neck cancer	0.00393	0.00393	CcSEcCtD
Deferoxamine—Infection—Docetaxel—head and neck cancer	0.0039	0.0039	CcSEcCtD
Deferoxamine—Shock—Docetaxel—head and neck cancer	0.00386	0.00386	CcSEcCtD
Deferoxamine—Nervous system disorder—Docetaxel—head and neck cancer	0.00385	0.00385	CcSEcCtD
Deferoxamine—Pruritus—Fluorouracil—head and neck cancer	0.00385	0.00385	CcSEcCtD
Deferoxamine—Thrombocytopenia—Docetaxel—head and neck cancer	0.00385	0.00385	CcSEcCtD
Deferoxamine—Tachycardia—Docetaxel—head and neck cancer	0.00383	0.00383	CcSEcCtD
Deferoxamine—Skin disorder—Docetaxel—head and neck cancer	0.00381	0.00381	CcSEcCtD
Deferoxamine—Diarrhoea—Fluorouracil—head and neck cancer	0.00372	0.00372	CcSEcCtD
Deferoxamine—Hypotension—Docetaxel—head and neck cancer	0.00367	0.00367	CcSEcCtD
Deferoxamine—Dizziness—Fluorouracil—head and neck cancer	0.0036	0.0036	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.00358	0.00358	CcSEcCtD
Deferoxamine—Paraesthesia—Docetaxel—head and neck cancer	0.00353	0.00353	CcSEcCtD
Deferoxamine—Dyspnoea—Docetaxel—head and neck cancer	0.0035	0.0035	CcSEcCtD
Deferoxamine—Vomiting—Fluorouracil—head and neck cancer	0.00346	0.00346	CcSEcCtD
Deferoxamine—Headache—Fluorouracil—head and neck cancer	0.00341	0.00341	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.00339	0.00339	CcSEcCtD
Deferoxamine—Pain—Docetaxel—head and neck cancer	0.00336	0.00336	CcSEcCtD
Deferoxamine—Nausea—Fluorouracil—head and neck cancer	0.00323	0.00323	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Docetaxel—head and neck cancer	0.00321	0.00321	CcSEcCtD
Deferoxamine—Abdominal pain—Docetaxel—head and neck cancer	0.0031	0.0031	CcSEcCtD
Deferoxamine—Body temperature increased—Docetaxel—head and neck cancer	0.0031	0.0031	CcSEcCtD
Deferoxamine—Hypersensitivity—Docetaxel—head and neck cancer	0.00289	0.00289	CcSEcCtD
Deferoxamine—Pruritus—Docetaxel—head and neck cancer	0.00278	0.00278	CcSEcCtD
Deferoxamine—Diarrhoea—Docetaxel—head and neck cancer	0.00269	0.00269	CcSEcCtD
Deferoxamine—Dizziness—Docetaxel—head and neck cancer	0.0026	0.0026	CcSEcCtD
Deferoxamine—Vomiting—Docetaxel—head and neck cancer	0.0025	0.0025	CcSEcCtD
Deferoxamine—Headache—Docetaxel—head and neck cancer	0.00246	0.00246	CcSEcCtD
Deferoxamine—Nausea—Docetaxel—head and neck cancer	0.00233	0.00233	CcSEcCtD
